


Risvodenitib

| | |
|--------------------|----------------------------------------------------------------------------------------------------|
| Cat. No.: | HY-148794 |
| CAS No.: | 2031185-00-7 |
| Molecular Formula: | C ₃₃ H ₃₄ N ₈ O ₂ |
| Molecular Weight: | 574.68 |
| Target: | c-Met/HGFR |
| Pathway: | Protein Tyrosine Kinase/RTK |
| Storage: | Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |



SOLVENT & SOLUBILITY

| | | | | | | |
|-------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|------|-----------|-----------|------------|
| In Vitro | DMSO : 100 mg/mL (174.01 mM; Need ultrasonic) | | | | | |
| | Preparing Stock Solutions | <div><div>Solvent</div><div>Concentration</div></div> | Mass | 1 mg | 5 mg | 10 mg |
| | | 1 mM | | 1.7401 mL | 8.7005 mL | 17.4010 mL |
| | | 5 mM | | 0.3480 mL | 1.7401 mL | 3.4802 mL |
| | | 10 mM | | 0.1740 mL | 0.8700 mL | 1.7401 mL |
| Please refer to the solubility information to select the appropriate solvent. | | | | | | |
| In Vivo | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.35 mM); Clear solution | | | | | |
| | 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (4.35 mM); Clear solution; Need ultrasonic | | | | | |
| | 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (4.35 mM); Clear solution; Need ultrasonic | | | | | |

BIOLOGICAL ACTIVITY

| | |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Description | Risvodenitib is a potent protein tyrosine kinase inhibitor. Risvodenitib involves in synthesis of Abelson protein kinases (c-Abl1, c-Abl2, and c-kit) inhibitor ^{[1][2]} . |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

REFERENCES

[1]. Werner MH, et al. Preparation of N-[3-[[4-(2-pyridyl)pyrimidin-2-yl]amino]phenyl]-4-[(piperazin-1-yl)methyl]benzamide derivatives as inhibitors of kinases: World

Intellectual Property Organization, WO2016172528. 2016-10-27.

[2]. WHO Drug Information-World Health Organization (WHO).

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA